Skip to main content
. 2023 Feb 10;25(3):127. doi: 10.3892/ol.2023.13713

Figure 4.

Figure 4.

(A) Comparison of recurrence-free survival between the s-JMJD6-Ab-positive group and s-JMJD6-Ab-negative groups. (B) Comparison of overall survival between the s-JMJD6-Ab positive group and s-JMJD6-Ab negative groups. The bottom row is a comparison by stage. The P-values were calculated by log-rank test based on Kaplan-Meier. Relapse-free survival and overall survival were significantly worse in the high s-JMJD6-Ab group than in the low s-JMJD6-Ab group (P=0.02, P=0.03). The antibody-positive group had a significantly poorer prognosis in stages I, II, and III than the antibody-negative groups. s-JMJD6-Ab, serum antibody against JMJD6.